Hilltop National Bank Reduces Stock Position in Repligen Co. (NASDAQ:RGEN)

Hilltop National Bank cut its stake in Repligen Co. (NASDAQ:RGEN) by 10.0% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 875 shares of the biotechnology company’s stock after selling 97 shares during the quarter. Hilltop National Bank’s holdings in Repligen were worth $126,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in RGEN. Champlain Investment Partners LLC increased its holdings in Repligen by 149.0% in the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after buying an additional 850,345 shares in the last quarter. Thrivent Financial for Lutherans grew its position in shares of Repligen by 240.5% in the second quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock valued at $75,866,000 after purchasing an additional 425,061 shares during the last quarter. DF Dent & Co. Inc. grew its position in shares of Repligen by 31.0% in the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after purchasing an additional 139,615 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Repligen by 39.4% in the second quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock valued at $54,149,000 after purchasing an additional 121,305 shares during the last quarter. Finally, Two Sigma Advisers LP grew its position in shares of Repligen by 421.9% in the third quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company’s stock valued at $18,796,000 after purchasing an additional 102,100 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on RGEN. Wolfe Research began coverage on shares of Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Canaccord Genuity Group began coverage on shares of Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. Canaccord Genuity Group initiated coverage on shares of Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. Finally, Royal Bank of Canada restated an “outperform” rating and set a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Repligen has an average rating of “Moderate Buy” and a consensus price target of $185.20.

Repligen Stock Up 0.1 %

Shares of RGEN opened at $154.86 on Friday. The firm has a market cap of $8.68 billion, a PE ratio of -418.53, a price-to-earnings-growth ratio of 4.64 and a beta of 0.97. The company’s fifty day moving average is $146.77 and its two-hundred day moving average is $143.29. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The company had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. Repligen’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter last year, the business earned $0.23 EPS. Analysts forecast that Repligen Co. will post 1.54 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.